This $4 Stock Could Be Your Ticket to Millionaire Status

Key Points

• It comes as no surprise that artificial intelligence is at the heart of the opportunity.

• This application of AI, in fact, is arguably one of the best uses of this young technology.

• The chief stumbling block is that the idea may be a little too far ahead of its time, with no barrier to entry when the time is right.

• 10 stocks we like better than Recursion Pharmaceuticals ›

What’s the best next use of artificial intelligence (AI)? Plenty of people would say drug development. And they’d arguably be right.

That’s not something for down the road, though, when AI is more refined. Recursion Pharmaceuticals (NASDAQ: RXRX) is doing it right now. Its platform called Recursion OS leverages 65 petabytes (65 million gigabytes) of chemical and biological information to virtually test a drug.

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »

Clinical trials that would normally take years and millions of dollars to complete can now be done with a fraction of both. Although the FDA still requires full-blown clinical testing, this virtual pretesting allows pharmaceutical companies to focus their limited resources on only their most promising prospects.

Image source: Getty Images.

This isn’t mere theory or premise, either. Drugs that were pretested with Recursion OS are now in actual clinical trials. All told, Recursion’s current developmental pipeline consists of eight drugs, half of which are in trials with real patients.

Although Recursion is working on some of its own drugs, in most cases, pharma companies compensate Recursion for access to its technology. To this end, analysts expect the company’s top line to improve from last year’s anticipated $62 million to $83 million this year en route to $163 million in 2028 as R&D milestone payments from some of its partners start flowing more freely. Revenue from actual pharmaceutical sales remains further down the road.

There’s still risk here, to be sure. Profitability is even further away than drug sales, for instance, and there’s not necessarily much to prevent a bigger tech company from crossing the industry’s low barrier to entry to become a direct competitor.

In light of Straits Research’s belief that the AI-powered drug development industry is set to grow at an average annual pace of 30% between now and 2034, however, perhaps the earliest name in the business to create a solution of Recursion OS’s caliber is also the name to put at the top of your watch list.

Just keep in mind this is very much an all-or-nothing kind of trade, with a big potential upside, but a big potential downside as well.

Should you buy stock in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*

Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 7, 2026.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.